JP2002504491A5 - - Google Patents

Download PDF

Info

Publication number
JP2002504491A5
JP2002504491A5 JP2000532434A JP2000532434A JP2002504491A5 JP 2002504491 A5 JP2002504491 A5 JP 2002504491A5 JP 2000532434 A JP2000532434 A JP 2000532434A JP 2000532434 A JP2000532434 A JP 2000532434A JP 2002504491 A5 JP2002504491 A5 JP 2002504491A5
Authority
JP
Japan
Prior art keywords
peptide analog
residue
residues
chain
human insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000532434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002504491A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/003915 external-priority patent/WO1999042482A1/en
Publication of JP2002504491A publication Critical patent/JP2002504491A/ja
Publication of JP2002504491A5 publication Critical patent/JP2002504491A5/ja
Pending legal-status Critical Current

Links

JP2000532434A 1998-02-23 1999-02-23 インスリンのペプチドアナログを使用した糖尿病の処置のための方法 Pending JP2002504491A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2815698A 1998-02-23 1998-02-23
US09/028,156 1998-02-23
PCT/US1999/003915 WO1999042482A1 (en) 1998-02-23 1999-02-23 Methods for treatment of diabetes using peptide analogues of insulin

Publications (2)

Publication Number Publication Date
JP2002504491A JP2002504491A (ja) 2002-02-12
JP2002504491A5 true JP2002504491A5 (enExample) 2006-03-23

Family

ID=21841884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000532434A Pending JP2002504491A (ja) 1998-02-23 1999-02-23 インスリンのペプチドアナログを使用した糖尿病の処置のための方法

Country Status (20)

Country Link
US (1) US6197926B1 (enExample)
EP (1) EP1056776A1 (enExample)
JP (1) JP2002504491A (enExample)
KR (1) KR20010041238A (enExample)
CN (1) CN1241942C (enExample)
AP (1) AP2000001888A0 (enExample)
AU (1) AU741037B2 (enExample)
BR (1) BR9908178A (enExample)
CA (1) CA2321929A1 (enExample)
EA (1) EA003944B1 (enExample)
HU (1) HUP0100928A3 (enExample)
ID (1) ID26788A (enExample)
IL (1) IL137904A0 (enExample)
NO (1) NO20004198L (enExample)
NZ (1) NZ506447A (enExample)
OA (1) OA11453A (enExample)
PL (1) PL342517A1 (enExample)
SK (1) SK12412000A3 (enExample)
TR (1) TR200003048T2 (enExample)
WO (1) WO1999042482A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
ATE367816T1 (de) * 2000-05-12 2007-08-15 Univ Oregon Health & Science Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
ZA200502613B (en) 2002-10-10 2006-10-25 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
JP2006526651A (ja) * 2003-06-02 2006-11-24 マーシア・ファーマ・インコーポレイテッド 1型糖尿病の処置のための治療的ワクチン組成物
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
HUE068164T2 (hu) 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
US8481485B2 (en) * 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2011056226A1 (en) 2009-11-05 2011-05-12 Mercia Pharma Llc Adjuvanted nanoparticulate influenza vaccine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US20110311536A1 (en) * 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
JP6657230B2 (ja) 2014-09-24 2020-03-04 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
CN111925420B (zh) * 2019-12-11 2022-04-01 山东大学 一种多肽作为嗅觉受体Olfr109激动剂配体的应用
USD1043348S1 (en) * 2021-09-24 2024-09-24 H.J. Heinz Company Brands Llc Bottle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5559094A (en) 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
EP0835129B1 (en) * 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes

Similar Documents

Publication Publication Date Title
JP2002504491A5 (enExample)
EP0528312A3 (en) Cyclic peptides and use thereof
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
AU2003264514A8 (en) Wt1 substitution peptides
PH12012502372A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
GB9930882D0 (en) GLP-2 formulations
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
YU71395A (sh) Acilovani analozi insulina
JP2002509854A5 (enExample)
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DK0482013T3 (da) Ikke-glycolyserede humant interleukin-3 analoge proteiner
CA2208274A1 (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
EP1399108A4 (en) PREPARATION OF A THERAPEUTIC COMPOSITION
WO2004009625A3 (en) PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES
IL102346A0 (en) Cysteine depleted il-6 muteins
NZ508816A (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
ATE323724T1 (de) Mpl-liganden analoga
WO2003099849A3 (en) Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
JP2004505616A5 (enExample)
ATE371737T1 (de) Proteaseresistente flint-analoge
WO2003097677A3 (fr) Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
AU1464488A (en) Human rhinovirus peptides
MY120083A (en) Process for the preparation of cyclo(asp-dphe-nmeval-arg-gly)
TW360661B (en) Superactive GRF analogs
ES2146555B1 (es) Empleo de formulaciones a base de fracciones hidrosolubles de phlebodium decumanum (exply-37) y/o polypodium leucotomos como complemento nutricional en la prevencion y reversion del sindrome de sobresfuerzo fisico.